AdvaMed may have won a seven-year fight to repeal the 2.3% medical device excise tax, but the largest medtech advocacy group is not resting on its laurels just yet. CEO Scott Whitaker says the next battlegrounds include reimbursement certainty for industry, access to international markets, ensuring realistic ethylene oxide (EtO) sterilization regulations, and more.
Industry Advocacy Group Goes Global After Device Tax Repeal
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.
